MIDDLE EAST AND ASIA PACIFIC CELL AND GENE THERAPY MARKET ANALYSIS

Market Challenges And Opportunities

Increasing launch and approval of novel gene therapies for the treatment of various rare diseases is expected to derive the market growth

In June 2017, Horama S.A. a biotechnology company announced that U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HORARLBP1. A gene replacement therapy Moreover, HORARLBP1 is developed for the treatment of retinitis punctata albescens and retinitis pigmentosa caused by mutations in the RLBP1 gene.

Cell and gene therapies (CGTs) are at the forefront of medical advancements in the treatment of serious diseases such as cancer, cardiovascular diseases, and others. Many more CGTs are currently being developed.

Middle East and Asia Pacific Cell and Gene Therapy Market: Restraint

Factor such as unfavorable reimbursement policies for cell and gene therapy products is expected to hamper the market growth over the forecast period.

Kymriah is a genetically-modified autologous T-cell immunotherapy has listed price of US$ 475,000 for patients with acute lymphocytic leukemia and US$ 373,000 for patients with large B-cell lymphoma; whereas, Yescarta has a listed price of US$ 373,000. Indicated for the treatment of adults with follicular lymphoma or certain types of large B-cell lymphoma Therefore, treatment with such a high price requires government support, in terms of reimbursement policy for a better adoption rate.

However, cell and gene therapy has witnessed multiple setbacks from regulatory authorities in charge of reimbursement policies, which is expected to hinder growth of the market.

• Unfavorable reimbursement policies for cell and gene therapy products
• Manufacturing issues limiting the availability of cell and gene therapy products at treatment centers